A prospective cohort study evaluates the efficacy of a newly introduced targeted therapy, a selective JAK inhibitor, in achieving clinical remission in adults with moderate-to-severe rheumatoid arthritis (RA). The primary outcome is clinical remission at weeks. The initial analysis reveals a crude relative risk (RR) of ( CI: ) for achieving clinical remission with the new therapy compared to standard care.
During peer review, concerns are raised that the patient's baseline autoantibody status (rheumatoid factor or anti-CCP positivity) might be influencing the results. The investigators perform a stratified analysis based on baseline serologic status. The results show:
- Seropositive patients: ( CI: )
- Seronegative patients: ( CI: )
Which of the following best describes the role of baseline serologic status in this study?
- AConfounding variable
- Effect modifierCevap
- CInformation bias
- DMediator variable
- ESelection bias